Evidence map›Paper›PMID 29293269›Full record

ArticleAnnals of neurology2018

Is multiple system atrophy an infectious disease?

Gregor Wenning, John Q Trojanowski, Horacio Kaufmann, Thomas Wisniewski, Walter A Rocca, Phillip A Low

Abstract readEditorial
In one paragraph

Article in Annals of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Is Multiple System Atrophy a Prion-like Disorder?International journal of molecular sciences · 2021
    Review
  4. Review
  5. Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease.Movement disorders : official journal of the Movement Disorder Society · 2021
    Article
  6. Article
  7. Article
  8. Synucleinopathies.Continuum (Minneapolis, Minn.) · 2020
    Review
  9. Article
  10. Review
  11. Review
  12. Dyskinesia in multiple system atrophy and progressive supranuclear palsy.Journal of neural transmission (Vienna, Austria : 1996) · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gregor WenningDepartment of Neurology, Innsbruck Medical University, Innsbruck, Austria.
John Q TrojanowskiDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Horacio KaufmannDepartment of Neurology, New York University School of Medicine, New York, NY.
Thomas WisniewskiDepartment of Neurology, New York University School of Medicine, New York, NY.
Walter A RoccaDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.ORCID 0000-0002-1832-7664
Phillip A LowDepartment of Neurology, Mayo Clinic, Rochester, MN.

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
PSYCHOSOCIAL COREP30AG008051 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SHAO, YONGZHAO · 1990 to 2019
$36.1M
UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
SEX STEROIDS, GROWTH FACTORS, &BONE CELL FUNCTIONP01AG004875 · NIA · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 1985 to 2019
$30.8M
Project IV: "Alpha-Synuclein Strains & Diverse Synucleinopathies"P50NS053488 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2007 to 2017
$20.9M
Studies on Diagnosis, Pathophysiology, and Treatment of Autonomic Failure in MSAP01NS044233 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOW, PHILLIP A · 2003 to 2014
$12.4M
Training CoreU54NS065736 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FREEMAN, ROY · 2009 to 2018
$11.6M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Synucleinopathies – Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic ApproachR01NS092625 · NINDS · MAYO CLINIC ROCHESTER · PI SINGER, WOLFGANG, VEMURI, PRASHANTHI · 2015 to 2025
$6.6M
Sex-specific Risk for Vascular Dysfunction and Cognitive DeclineP50AG044170 · NIA · MAYO CLINIC ROCHESTER · PI MILLER, VIRGINIA M · 2012 to 2017
$6.1M
Therapeutic Targeting of Abnormal Conformation in Neurodegenerative DiseaseR01NS073502 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WISNIEWSKI, THOMAS M · 2010 to 2019
$3.7M
Multiple Chronic Conditions and AgingR01AG052425 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2017 to 2021
$3.3M
FDA HHS R01 FD004789NIA NIH HHS P01 AG004875NIA NIH HHS P30 AG008051NIA NIH HHS P30 AG010124NIA NIH HHS P50 AG044170NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG052425NIA NIH HHS U01 AG006786NINDS NIH HHS P01 NS044233NINDS NIH HHS P50 NS053488NINDS NIH HHS R01 NS073502NINDS NIH HHS R01 NS092625NINDS NIH HHS U54 NS065736
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

alpha-SynucleinCommunicable DiseasesHumansMultiple System AtrophyPrion DiseasesProteostasis Deficienciesalpha-Synuclein

Identifiers

PMID29293269
PMCPMC5876125

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.